Format
Items per page
Sort by

Send to:

Choose Destination

Results: 13

Related Articles by Review for PubMed (Select 21953021)

1.

A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer.

Ali HR, Dawson SJ, Blows FM, Provenzano E, Leung S, Nielsen T, Pharoah PD, Caldas C.

J Pathol. 2012 Jan;226(1):97-107. doi: 10.1002/path.2976. Epub 2011 Sep 26.

PMID:
21953021
2.

Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer.

Callagy GM, Webber MJ, Pharoah PD, Caldas C.

BMC Cancer. 2008 May 29;8:153. doi: 10.1186/1471-2407-8-153. Review.

3.

Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis.

Vera-Badillo FE, Templeton AJ, de Gouveia P, Diaz-Padilla I, Bedard PL, Al-Mubarak M, Seruga B, Tannock IF, Ocana A, Amir E.

J Natl Cancer Inst. 2014 Jan;106(1):djt319. doi: 10.1093/jnci/djt319. Epub 2013 Nov 22. Review.

4.

Correlation between Ki67 and breast cancer prognosis.

Kontzoglou K, Palla V, Karaolanis G, Karaiskos I, Alexiou I, Pateras I, Konstantoudakis K, Stamatakos M.

Oncology. 2013;84(4):219-25. doi: 10.1159/000346475. Epub 2013 Jan 24. Review.

PMID:
23364275
5.

Influence of genomics on adjuvant treatments for pre-invasive and invasive breast cancer.

Abu-Khalf M, Pusztai L.

Breast. 2013 Aug;22 Suppl 2:S83-7. doi: 10.1016/j.breast.2013.07.015. Review.

PMID:
24074799
6.

Ki67 and proliferation in breast cancer.

Pathmanathan N, Balleine RL.

J Clin Pathol. 2013 Jun;66(6):512-6. doi: 10.1136/jclinpath-2012-201085. Epub 2013 Feb 22. Review.

PMID:
23436927
7.

Triple negative breast cancer - BCL2 in prognosis and prediction. Review.

Bouchalova K, Kharaishvili G, Bouchal J, Vrbkova J, Megova M, Hlobilkova A.

Curr Drug Targets. 2014;15(12):1166-75. Review.

PMID:
25374001
8.

Prognostic value of proliferation in invasive breast cancer: a review.

van Diest PJ, van der Wall E, Baak JP.

J Clin Pathol. 2004 Jul;57(7):675-81. Review.

9.

Ki67 in breast cancer: prognostic and predictive potential.

Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA.

Lancet Oncol. 2010 Feb;11(2):174-83. doi: 10.1016/S1470-2045(09)70262-1. Review.

PMID:
20152769
10.

Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful?

Hayes DF, Trock B, Harris AL.

Breast Cancer Res Treat. 1998;52(1-3):305-19. Review.

PMID:
10066089
11.

Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines.

Mallett S, Timmer A, Sauerbrei W, Altman DG.

Br J Cancer. 2010 Jan 5;102(1):173-80. doi: 10.1038/sj.bjc.6605462. Epub 2009 Dec 8. Review.

12.

Publication of tumor marker research results: the necessity for complete and transparent reporting.

McShane LM, Hayes DF.

J Clin Oncol. 2012 Dec 1;30(34):4223-32. doi: 10.1200/JCO.2012.42.6858. Epub 2012 Oct 15. Review.

13.

Significance of immunohistochemistry in breast cancer.

Zaha DC.

World J Clin Oncol. 2014 Aug 10;5(3):382-92. doi: 10.5306/wjco.v5.i3.382. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk